VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 33.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $202.00 thousand which beat the analyst consensus estimate of $50.00 thousand by 304.00 percent. This is a 106.12 percent increase over sales of $98.00 thousand the same period last year.